echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Express "first-in-class" new target!

    Express "first-in-class" new target!

    • Last Update: 2021-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎The content team editor of WuXi AppTec today, Trigone Pharma announced that it has reached a strategic cooperation agreement with 4C Biomed to develop a new type of intravesical immunotherapy
    .

    The therapy is delivered directly to the bladder for the treatment of high-grade non-muscular invasive bladder cancer (HG-NMIBC)
    .

    This method involves the local delivery of 4C Biomed's potential "first-in-class" monoclonal antibody, which targets the herpes virus entry medium (HVEM, also known as TNFRSF14)
    .

    This therapy will use Trigone's proprietary delivery technology to increase the residence time of the drug, which has been shown to significantly improve the effectiveness of bladder targeted therapy
    .

    HVEM is a member of the tumor necrosis factor receptor family and was originally discovered as the entry route for herpes simplex virus (HSV)
    .

    It is expressed on the surface of T cells, B cells and other hematopoietic cells, as well as on endothelial and epithelial cells
    .

    HVEM interacts with the inhibitory receptor B on tumor-specific T cells and the T lymphocyte-associated receptor (BTLA), resulting in T cell suppression
    .

    Anti-4CB-1 antibody is a fully human anti-HVEM monoclonal antibody that can specifically block the HVEM-BTLA interaction, leading to immune cell activation, and subsequently enhancing cytotoxicity to cancer cells
    .

    ▲The mechanism of action of the anti-4CB-1 antibody (picture source: 4C Biomed's official website) "We are very pleased to reach this cooperation with 4C Biomed
    .

    "Trigone Chief Medical Officer Dr.
    Ofer Nativ said, "We believe that this unique combination will take advantage of the strengths of each technology and may develop a promising and powerful immunotherapy for bladder with limited clinical options other than cystectomy.
    Cancer patients, they have significant unfulfilled needs
    .

    "4C Biomed CEO and scientific co-founder Dr.
    Eyal Greenberg said: "Immunotherapy has become an important treatment option for many patients with bladder cancer.
    We look forward to working with Trigone to promote new immunotherapy strategies for bladder perfusion
    .

    This new delivery method has the potential to enhance the bioavailability of our anti-HVEM antibody in the bladder, and enhance its anti-cancer efficacy, while providing clinical benefits, which will represent a major advancement in patient care
    .

    "Reference: [1] Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer.
    Retrieved September 20, 2021, from https:// /09/20/2299879/0/en/Trigone-Pharma-Announces-a-Strategic-Collaboration-with-4C-Biomed-to-Develop-a-Novel-Treatment-for-High-Grade-Bladder-Cancer.
    html Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
    .

    This article is for information exchange purposes only.
    The views in the article do not represent WuXi AppTec's position, nor do it mean that WuXi AppTec supports or opposes the views in the article
    .

    This article is not a treatment recommendation either
    .

    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.